COMMUNIQUÉS West-GlobeNewswire

Avacta Announces Year-end Trading Update
20/01/2026
LONDON and PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology delivery platform, has [...]
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
20/01/2026
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injury Participants to include people with Long COVID who [...]
Kraig Biocraft Laboratories Rings in the New Year with the Most Ambitious Genetic Engineering Program in its History
20/01/2026
ANN ARBOR, Mich., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced that it is [...]
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
20/01/2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced effective date of its [...]
Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
20/01/2026
The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout and partnering [...]
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
20/01/2026
FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of [...]
Glass House Brands Announces Accelerated 2026 Expansion Strategy
20/01/2026
The Company is accelerating expansion efforts with plans to commence production in two additional greenhouses and planting its first production intended for sale in markets outside of California. Accelerated expansion [...]
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
20/01/2026
- Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE Registrational [...]
Reunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) at ACNP Annual Meeting
20/01/2026
-- Met Primary Endpoint with 30mg Dose of RE104 with 23.0-Point Total Score Reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) on Day 7 (p=0.0094) -- -- Demonstrated Rapid and Durable Efficacy Starting as [...]
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
20/01/2026
-- Designation highlights significant unmet medical need AUSTIN, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in- [...]
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
20/01/2026
- PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in [...]
SpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials of Its Novel BIM-IOL System
20/01/2026
ALISO VIEJO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical [...]
Korro to Host Virtual Analyst Day on January 27, 2026
20/01/2026
- Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia , a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing [...]
Catheter Precision Received new VIVO Purchase Order from Leading Hospital in Slovenia
20/01/2026
Expands Global Footprint to 15 Countries FORT MILL, S.C., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically [...]
electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million
20/01/2026
Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 Revenue growth of approximately 26% over full-year 2024 Cash, [...]
Alignment Health Appoints Adnan Mansour as Chief Digital Officer to Accelerate AI-Driven Growth and Technology Leadership
20/01/2026
Industry veteran brings decades of experience in artificial intelligence, digital transformation and large-scale technology operations to support Alignment’s next phase of growth ORANGE, Calif., Jan. 20, 2026 (GLOBE [...]
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
20/01/2026
BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of [...]
Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
20/01/2026
Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen ® 91% of study participants achieved the 100 pg/ml plasma threshold at 5 minutes with [...]
Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium™
20/01/2026
LONDON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 and GALILEO-2 trials of avigbagene parvec (FLT201), its Phase 3 gene [...]

Pages